MedTrace Logo

The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

NCT01259141 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2015-07-28

No results posted yet for this study

Summary

Mycoplasma pneumoniae, an important pathogen of community acquired pneumonia,are becoming more and more resistant to macrolide. The study aim is to optimize anti-infection therapy.

Conditions

  • Mycoplasma Pneumonia

Interventions

DRUG

Moxifloxacin

0.4 Qd for 7days

DRUG

Cephalosporins and azithromycin

cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Principal Investigators

  • Bin Cao, Doctor · Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01259141 on ClinicalTrials.gov